---
layout: post
title: "Prospective Grant of Exclusive Patent License: Chimeric Antigen Receptors Targeting CD56"
date: 2026-02-05 19:09:00 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-06474
original_published: 2021-03-30 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Chimeric Antigen Receptors Targeting CD56

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** March 30, 2021 00:00 UTC
**Document Number:** 2021-06474

## Summary

The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Memorial Sloan Kettering Cancer Center, ("MSKCC"), a non-profit research center located in New York, in its rights to the inventions and patents listed in the SUPPLEMENTARY INFORMATION section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/30/2021-06474/prospective-grant-of-exclusive-patent-license-chimeric-antigen-receptors-targeting-cd56)
- API: https://www.federalregister.gov/api/v1/documents/2021-06474

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
